

N9-GP Prophylaxis in Children: Safety including neurodevelopment and efficacy for up to 8 years



SANTIAGO ARREDONDO
Santiago has haemophilia B
Mexico

17:30 – 17:35

Welcome and introduction
Sonata Šaulytė Trakymienė (LT)



17:35 – 17:50

Improvement and remaining gaps in Haemophilia B treatment
Sonata Šaulytė Trakymienė (LT)

17:50 – 18:10

Up to 8 years of safety and efficacy outcomes from children trials (PUPs and PTPs)
Manuel Carcao (CA)



18:10 – 18:35

Neurodevelopment in children on N9-GP prophylaxis
Helle Holst (DK)



18:35 – 18:45

Q&A and meeting closure
All



Wednesday, 07 February 2024

17:30 - 18:45 CET



ROOM
Panorama 3